お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
365178

大腸癌:疫学・患者に基づく市場予測、治療アルゴリズム、上市薬・パイプライン薬の分析

Colorectal Cancer Forecast and Market Analysis to 2036

出版日: | 発行: Datamonitor Healthcare | ページ情報: 英文 630 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=104.68円
大腸癌:疫学・患者に基づく市場予測、治療アルゴリズム、上市薬・パイプライン薬の分析
出版日: 2018年09月06日
発行: Datamonitor Healthcare
ページ情報: 英文 630 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 目次
概要

当レポートでは、大腸癌治療薬市場について調査分析し、市場予測、治療、疫学、上市薬、パイプライン薬の動向など、体系的な情報を提供しています。

予測:大腸癌

  • エグゼクティブサマリー
  • 市場概要・動向
  • 手法・市場定義
  • Avastin (bevacizumab)
  • CPP-1X (eflornithine/sulindac)
  • Cyramza (ramucirumab)
  • Erbitux (cetuximab)
  • Imprime PGG
  • Keytruda (pembrolizumab)
  • Lonsurf (trifluridine/tipiracil)
  • Masitinib
  • MGN1703 (lefitolimod)
  • Ofev (nintedanib)
  • OncoVAX
  • Stivarga (regorafenib)
  • TS-1 (gimeracil/oteracil potassium/tegafur)
  • Vectibix (panitumumab)
  • Xilonix
  • Zaltrap (aflibercept)
  • 1次調査手法

治療:米国・日本・EU5ヶ国の大腸癌

  • エグゼクティブサマリー
  • 疾患の定義・診断
  • 患者区分
  • 現在の治療オプション
  • I期・II期
  • III期
  • IV期
  • 調査手法

疫学:米国・日本・EU5ヶ国の大腸癌

  • エグゼクティブサマリー
  • 疾患の定義
  • 世界の変動
  • 危険因子
  • 情報源・手法
  • 予測
  • 疫学者の考察
  • 長所・短所
  • 参考文献

上市薬:大腸癌

  • エグゼクティブサマリー
  • 製品概要
  • その他の上市薬
  • 製品プロファイル:Avastin
  • 製品プロファイル:Camptosar
  • 製品プロファイル:Cyramza
  • 製品プロファイル:Eloxatin
  • 製品プロファイル:Erbitux
  • 製品プロファイル:Lonsurf
  • 製品プロファイル:Stivarga
  • 製品プロファイル:Vectibix
  • 製品プロファイル:Xeloda
  • 製品プロファイル:Zaltrap

パイプライン:大腸癌

  • エグゼクティブサマリー
  • 臨床パイプラインの概要
  • 製品プロファイル (後期) :CPP-1X/sulindac
  • 製品プロファイル (後期) :Imprime PGG
  • 製品プロファイル (後期) :Keytruda
  • 製品プロファイル (後期) :MGN1703
  • 製品プロファイル (後期) :Ofev
  • 製品プロファイル (後期) :OncoVAX
  • 製品プロファイル (後期) :Xilonix
  • 製品プロファイル (後期) :masitinib
目次
Product Code: DMKC10877

Overview

Colorectal cancer (CRC) is one of the "big four" tumor types, the third most common cancer to affect both men and women, and the third-leading cause of cancer-related death. The main differentiator between colon cancer and rectal cancer is the location of the primary tumor, but identical etiology and similar risk factors and symptoms mean that they are often grouped together. CRC is believed to arise as a result of interactions between inherited and environmental factors. Despite improved prognosis of CRC patients in the last decade following advances in treatment options, survival rates still lag behind those of breast and prostate cancer patients.

Market Snapshot

  • Avastin will remain the leading targeted therapy in the colorectal cancer market through to 2025. Avastin in combination with FOLFOX remains the most commonly prescribed first-line treatment for Stage IV disease.
  • By 2037, diagnosed incident cases of colorectal cancer are forecast to increase by 27.3% to 672,400 cases.
  • A number of leading drugs will soon face biosimilar competition.
  • Pipeline candidates will use novel mechanisms of action as distinguishing factors in an increasingly crowded market.

TABLE OF CONTENTS

FORECAST: COLORECTAL CANCER (Published on 11 December 2017)

  • OVERVIEW
  • EXECUTIVE SUMMARY
  • RECENT FORECAST UPDATES
  • MARKET DYNAMICS
  • FORECAST AND FUTURE TRENDS
  • MARKET DEFINITION AND METHODOLOGY
  • PRIMARY RESEARCH METHODOLOGY
  • BIBLIOGRAPHY
  • PRODUCT PROFILE: AVASTIN
  • PRODUCT PROFILE (LATE STAGE): COTELLIC
  • PRODUCT PROFILE: CYRAMZA
  • PRODUCT PROFILE: ERBITUX
  • PRODUCT PROFILE: KEYTRUDA
  • PRODUCT PROFILE: LONSURF
  • PRODUCT PROFILE (LATE STAGE): ONCOVAX
  • PRODUCT PROFILE: OPDIVO
  • PRODUCT PROFILE: STIVARGA
  • PRODUCT PROFILE: TS-1
  • PRODUCT PROFILE (LATE STAGE): TECENTRIQ
  • PRODUCT PROFILE: VECTIBIX
  • PRODUCT PROFILE: ZALTRAP
  • PRODUCT PROFILE (LATE STAGE): BINIMETINIB
  • PRODUCT PROFILE (LATE STAGE): LEFITOLIMOD
  • PRODUCT PROFILE (LATE STAGE): MASITINIB
  • PRODUCT PROFILE (LATE STAGE): NAPABUCASIN

TREATMENT: COLORECTAL CANCER (Published on 25 August 2017)

  • OVERVIEW
  • EXECUTIVE SUMMARY
  • PRIMARY RESEARCH METHODOLOGY
  • DISEASE DEFINITION AND DIAGNOSIS
  • PATIENT SEGMENTATION
  • CURRENT TREATMENT OPTIONS
  • PRESCRIBING TRENDS

EPIDEMIOLOGY: COLORECTAL CANCER (Published on 06 September 2018)

  • OVERVIEW
  • DISEASE BACKGROUND
  • METHODOLOGY
  • FORECAST
  • BIBLIOGRAPHY
  • APPENDIX

MARKETED DRUGS: COLORECTAL CANCER (Published on 11 December 2017)

  • OVERVIEW
  • EXECUTIVE SUMMARY
  • PRODUCT OVERVIEW
  • PRODUCT PROFILE: AVASTIN
  • PRODUCT PROFILE: CYRAMZA
  • PRODUCT PROFILE: ERBITUX
  • PRODUCT PROFILE: KEYTRUDA
  • PRODUCT PROFILE: LONSURF
  • PRODUCT PROFILE: OPDIVO
  • PRODUCT PROFILE: STIVARGA
  • PRODUCT PROFILE: TS-1
  • PRODUCT PROFILE: VECTIBIX
  • PRODUCT PROFILE: ZALTRAP

PIPELINE: COLORECTAL CANCER (Published on 11 December 2017)

  • OVERVIEW
  • EXECUTIVE SUMMARY
  • CLINICAL PIPELINE OVERVIEW
  • ADDITIONAL PHARMA INTELLIGENCE PIPELINE RESOURCES
  • PRODUCT PROFILE (LATE STAGE): COTELLIC
  • PRODUCT PROFILE (LATE STAGE): ONCOVAX
  • PRODUCT PROFILE (LATE STAGE): TECENTRIQ
  • PRODUCT PROFILE (LATE STAGE): BINIMETINIB
  • PRODUCT PROFILE (LATE STAGE): ENCORAFENIB
  • PRODUCT PROFILE (LATE STAGE): LEFITOLIMOD
  • PRODUCT PROFILE (LATE STAGE): MASITINIB
  • PRODUCT PROFILE (LATE STAGE): NAPABUCASIN

LIST OF FIGURES

  • Figure 1: Colorectal cancer - current and future market dynamics analysis
  • Figure 2: Datamonitor Healthcare's assessment summary of key marketed and pipeline drugs for colorectal cancer
  • Figure 3: Colorectal cancer sales across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 4: Second- and third-line pipeline colorectal cancer drug sales across the US, Japan, and five major EU markets, by brand, 2016-25
  • Figure 5: PD-1/PD-L1 drug sales in colorectal cancer across the US, Japan, and five major EU markets, by brand, 2016-25
  • Figure 6: Colorectal cancer sales across the US, Japan, and five major EU markets, by class, 2016-25
  • Figure 7: Patient-based forecast methodology for colorectal cancer
  • Figure 8: Price sources and calculations, by country
  • Figure 9: Avastin for colorectal cancer - SWOT analysis
  • Figure 10: Datamonitor Healthcare's drug assessment summary of Avastin for colorectal cancer
  • Figure 11: Datamonitor Healthcare's drug assessment summary of Avastin for colorectal cancer
  • Figure 12: Avastin sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 13: Cotellic for colorectal cancer - SWOT analysis
  • Figure 14: Datamonitor Healthcare's drug assessment summary of Cotellic for colorectal cancer
  • Figure 15: Datamonitor Healthcare's drug assessment summary of Cotellic for colorectal cancer
  • Figure 16: Cotellic sales for colorectal cancer across the US and five major EU markets, by country, 2016-25
  • Figure 17: Cyramza for colorectal cancer - SWOT analysis
  • Figure 18: Datamonitor Healthcare's drug assessment summary of Cyramza for colorectal cancer
  • Figure 19: Datamonitor Healthcare's drug assessment summary of Cyramza for colorectal cancer
  • Figure 20: Cyramza sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 21: Erbitux for colorectal cancer - SWOT analysis
  • Figure 22: Datamonitor Healthcare's drug assessment summary of Erbitux for colorectal cancer
  • Figure 23: Datamonitor Healthcare's drug assessment summary of Erbitux for colorectal cancer
  • Figure 24: Erbitux sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 25: Keytruda for colorectal cancer - SWOT analysis
  • Figure 26: Datamonitor Healthcare's drug assessment summary for Keytruda in colorectal cancer
  • Figure 27: Datamonitor Healthcare's drug assessment summary for Keytruda in colorectal cancer
  • Figure 28: Keytruda sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 29: Lonsurf for colorectal cancer - SWOT analysis
  • Figure 30: Datamonitor Healthcare's drug assessment summary of Lonsurf for colorectal cancer
  • Figure 31: Datamonitor Healthcare's drug assessment summary of Lonsurf for colorectal cancer
  • Figure 32: Lonsurf sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 33: OncoVAX for colon cancer - SWOT analysis
  • Figure 34: Datamonitor Healthcare's drug assessment summary of OncoVAX for colon cancer
  • Figure 35: Datamonitor Healthcare's drug assessment summary of OncoVAX for colon cancer
  • Figure 36: OncoVAX sales for colon cancer in the US, 2016-25
  • Figure 37: Opdivo for colorectal cancer - SWOT analysis
  • Figure 38: Datamonitor Healthcare's drug assessment summary of Opdivo for colorectal cancer
  • Figure 39: Datamonitor Healthcare's drug assessment summary of Opdivo for colorectal cancer
  • Figure 40: Opdivo sales for colorectal cancer across the US and five major EU markets, by country, 2016-25
  • Figure 41: Stivarga for colorectal cancer - SWOT analysis
  • Figure 42: Datamonitor Healthcare's drug assessment summary of Stivarga for colorectal cancer
  • Figure 43: Datamonitor Healthcare's drug assessment summary of Stivarga for colorectal cancer
  • Figure 44: Stivarga sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 45: TS-1 for colorectal cancer - SWOT analysis
  • Figure 46: Datamonitor Healthcare's drug assessment summary of TS-1 in colorectal cancer
  • Figure 47: Datamonitor Healthcare's drug assessment summary of TS-1 in colorectal cancer
  • Figure 48: TS-1 sales for colorectal cancer in Japan, 2016-25
  • Figure 49: Tecentriq for colorectal cancer - SWOT analysis
  • Figure 50: Datamonitor Healthcare's drug assessment summary of Tecentriq for colorectal cancer
  • Figure 51: Datamonitor Healthcare's drug assessment summary of Tecentriq for colorectal cancer
  • Figure 52: Tecentriq sales for colorectal cancer across the US and five major EU markets, by country, 2016-25
  • Figure 53: Vectibix for colorectal cancer - SWOT analysis
  • Figure 54: Datamonitor Healthcare's drug assessment summary of Vectibix for colorectal cancer
  • Figure 55: Datamonitor Healthcare's drug assessment summary of Vectibix for colorectal cancer
  • Figure 56: Vectibix sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 57: Zaltrap for colorectal cancer - SWOT analysis
  • Figure 58: Datamonitor Healthcare's drug assessment summary of Zaltrap for colorectal cancer
  • Figure 59: Datamonitor Healthcare's drug assessment summary of Zaltrap for colorectal cancer
  • Figure 60: Zaltrap sales for colorectal cancer across the US and five major EU markets, by country, 2016-25
  • Figure 61: Binimetinib for colorectal cancer - SWOT analysis
  • Figure 62: Datamonitor Healthcare's drug assessment summary for binimetinib in colorectal cancer
  • Figure 63: Datamonitor Healthcare's drug assessment summary for binimetinib in colorectal cancer
  • Figure 64: Binimetinib sales for colorectal cancer across the US and five major EU markets, by country, 2016-25
  • Figure 65: Lefitolimod for colorectal cancer - SWOT analysis
  • Figure 66: Datamonitor Healthcare's drug assessment summary for lefitolimod in colorectal cancer
  • Figure 67: Datamonitor Healthcare's drug assessment summary for lefitolimod in colorectal cancer
  • Figure 68: Lefitolimod sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 69: Masitinib for colorectal cancer - SWOT analysis
  • Figure 70: Datamonitor Healthcare's drug assessment summary for masitinib in colorectal cancer
  • Figure 71: Datamonitor Healthcare's drug assessment summary for masitinib in colorectal cancer
  • Figure 72: Masitinib sales for colorectal cancer across the US and five major EU markets, by country, 2016-25
  • Figure 73: Napabucasin for colorectal cancer - SWOT analysis
  • Figure 74: Datamonitor Healthcare's drug assessment summary for napabucasin in colorectal cancer
  • Figure 75: Datamonitor Healthcare's drug assessment summary for napabucasin in colorectal cancer
  • Figure 76: Napabucasin sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 77: Distribution of colorectal cancer patients across the US, Japan, and five major EU markets, by stage (%)
  • Figure 78: Percentage of Stage I and Stage II colorectal cancer patients receiving each type of treatment, by country
  • Figure 79: Percentage of Stage III colorectal cancer patients receiving each type of treatment, by country
  • Figure 80: Percentage of Stage III colorectal cancer patients treated with surgery and systemic therapy who receive neoadjuvant or adjuvant therapy, by country
  • Figure 81: Top three regimens used in the adjuvant treatment of Stage III colorectal cancer patients, by country
  • Figure 82: Percentage of Stage IV colorectal cancer patients receiving each treatment type, by country
  • Figure 83: Top three regimens used in the first-line treatment of Stage IV colorectal cancer patients receiving systemic therapy without surgery, by country
  • Figure 84: Top three regimens used in the first-line maintenance treatment of Stage IV colorectal cancer patients, by country
  • Figure 85: Percentage of Stage IV colorectal cancer patients currently receiving each line of therapy, by country
  • Figure 86: Top three regimens used for second-line treatment of Stage IV colorectal cancer patients, by country
  • Figure 87: Top three regimens used for third-line treatment of Stage IV colorectal cancer patients, by country
  • Figure 88: Percentage of local relapse colorectal cancer patients receiving each treatment type, by country
  • Figure 89: Top three regimens used in the adjuvant treatment of local relapse colorectal cancer patients, by country
  • Figure 90: Percentage of distant relapse colorectal cancer patients receiving each treatment type, by country
  • Figure 91: Top three regimens used in the first-line treatment of distant relapse CRC patients receiving systemic therapy without surgery, by country
  • Figure 92: Trends in incident cases of colorectal cancer in the US, Japan, and five major EU markets, by country, 2017-37
  • Figure 93: Avastin for colorectal cancer - SWOT analysis
  • Figure 94: Datamonitor Healthcare's drug assessment summary of Avastin for colorectal cancer
  • Figure 95: Datamonitor Healthcare's drug assessment summary of Avastin for colorectal cancer
  • Figure 96: Avastin sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 97: Cyramza for colorectal cancer - SWOT analysis
  • Figure 98: Datamonitor Healthcare's drug assessment summary of Cyramza for colorectal cancer
  • Figure 99: Datamonitor Healthcare's drug assessment summary of Cyramza for colorectal cancer
  • Figure 100: Cyramza sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 101: Erbitux for colorectal cancer - SWOT analysis
  • Figure 102: Datamonitor Healthcare's drug assessment summary of Erbitux for colorectal cancer
  • Figure 103: Datamonitor Healthcare's drug assessment summary of Erbitux for colorectal cancer
  • Figure 104: Erbitux sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 105: Keytruda for colorectal cancer - SWOT analysis
  • Figure 106: Datamonitor Healthcare's drug assessment summary for Keytruda in colorectal cancer
  • Figure 107: Datamonitor Healthcare's drug assessment summary for Keytruda in colorectal cancer
  • Figure 108: Keytruda sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 109: Lonsurf for colorectal cancer - SWOT analysis
  • Figure 110: Datamonitor Healthcare's drug assessment summary of Lonsurf for colorectal cancer
  • Figure 111: Datamonitor Healthcare's drug assessment summary of Lonsurf for colorectal cancer
  • Figure 112: Lonsurf sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 113: Opdivo for colorectal cancer - SWOT analysis
  • Figure 114: Datamonitor Healthcare's drug assessment summary of Opdivo for colorectal cancer
  • Figure 115: Datamonitor Healthcare's drug assessment summary of Opdivo for colorectal cancer
  • Figure 116: Opdivo sales for colorectal cancer across the US and five major EU markets, by country, 2016-25
  • Figure 117: Stivarga for colorectal cancer - SWOT analysis
  • Figure 118: Datamonitor Healthcare's drug assessment summary of Stivarga for colorectal cancer
  • Figure 119: Datamonitor Healthcare's drug assessment summary of Stivarga for colorectal cancer
  • Figure 120: Stivarga sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 121: TS-1 for colorectal cancer - SWOT analysis
  • Figure 122: Datamonitor Healthcare's drug assessment summary of TS-1 in colorectal cancer
  • Figure 123: Datamonitor Healthcare's drug assessment summary of TS-1 in colorectal cancer
  • Figure 124: TS-1 sales for colorectal cancer in Japan, 2016-25
  • Figure 125: Vectibix for colorectal cancer - SWOT analysis
  • Figure 126: Datamonitor Healthcare's drug assessment summary of Vectibix for colorectal cancer
  • Figure 127: Datamonitor Healthcare's drug assessment summary of Vectibix for colorectal cancer
  • Figure 128: Vectibix sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 129: Zaltrap for colorectal cancer - SWOT analysis
  • Figure 130: Datamonitor Healthcare's drug assessment summary of Zaltrap for colorectal cancer
  • Figure 131: Datamonitor Healthcare's drug assessment summary of Zaltrap for colorectal cancer
  • Figure 132: Zaltrap sales for colorectal cancer across the US and five major EU markets, by country, 2016-25
  • Figure 133: Cotellic for colorectal cancer - SWOT analysis
  • Figure 134: Datamonitor Healthcare's drug assessment summary of Cotellic for colorectal cancer
  • Figure 135: Datamonitor Healthcare's drug assessment summary of Cotellic for colorectal cancer
  • Figure 136: Cotellic sales for colorectal cancer across the US and five major EU markets, by country, 2016-25
  • Figure 137: OncoVAX for colon cancer - SWOT analysis
  • Figure 138: Datamonitor Healthcare's drug assessment summary of OncoVAX for colon cancer
  • Figure 139: Datamonitor Healthcare's drug assessment summary of OncoVAX for colon cancer
  • Figure 140: OncoVAX sales for colon cancer in the US, 2016-25
  • Figure 141: Tecentriq for colorectal cancer - SWOT analysis
  • Figure 142: Datamonitor Healthcare's drug assessment summary of Tecentriq for colorectal cancer
  • Figure 143: Datamonitor Healthcare's drug assessment summary of Tecentriq for colorectal cancer
  • Figure 144: Tecentriq sales for colorectal cancer across the US and five major EU markets, by country, 2016-25
  • Figure 145: Binimetinib for colorectal cancer - SWOT analysis
  • Figure 146: Datamonitor Healthcare's drug assessment summary for binimetinib in colorectal cancer
  • Figure 147: Datamonitor Healthcare's drug assessment summary for binimetinib in colorectal cancer
  • Figure 148: Binimetinib sales for colorectal cancer across the US and five major EU markets, by country, 2016-25
  • Figure 149: Encorafenib for colorectal cancer - SWOT analysis
  • Figure 150: Datamonitor Healthcare's drug assessment summary for encorafenib in colorectal cancer
  • Figure 151: Datamonitor Healthcare's drug assessment summary for encorafenib in colorectal cancer
  • Figure 152: Encorafenib sales for colorectal cancer across the US and five major EU markets, by country, 2016-25
  • Figure 153: Lefitolimod for colorectal cancer - SWOT analysis
  • Figure 154: Datamonitor Healthcare's drug assessment summary for lefitolimod in colorectal cancer
  • Figure 155: Datamonitor Healthcare's drug assessment summary for lefitolimod in colorectal cancer
  • Figure 156: Lefitolimod sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 157: Masitinib for colorectal cancer - SWOT analysis
  • Figure 158: Datamonitor Healthcare's drug assessment summary for masitinib in colorectal cancer
  • Figure 159: Datamonitor Healthcare's drug assessment summary for masitinib in colorectal cancer
  • Figure 160: Masitinib sales for colorectal cancer across the US and five major EU markets, by country, 2016-25
  • Figure 161: Napabucasin for colorectal cancer - SWOT analysis
  • Figure 162: Datamonitor Healthcare's drug assessment summary for napabucasin in colorectal cancer
  • Figure 163: Datamonitor Healthcare's drug assessment summary for napabucasin in colorectal cancer
  • Figure 164: Napabucasin sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016-25

LIST OF TABLES

  • Table 1: Colorectal cancer sales across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 2: PD-1/PD-L1 colorectal cancer drug sales across the US, Japan, and five major EU markets, by brand ($m), 2016-25
  • Table 3: Colorectal cancer sales across the US, Japan, and five major EU markets, by brand and class ($m), 2016-25
  • Table 4: Summary of drug classes and molecules included in Datamonitor Healthcare's colorectal cancer patient-based forecast
  • Table 5: Exchange rates used for calculating prices
  • Table 6: Medical oncologists and gastroenterologists surveyed for the colorectal cancer primary research study, 2016
  • Table 7: Avastin drug profile
  • Table 8: Overview of major approvals for Avastin in colorectal cancer
  • Table 9: Avastin Phase III data in colorectal cancer
  • Table 10: Avastin sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 11: Patients treated with Avastin across the US, Japan, and five major EU markets, by country, 2016-25
  • Table 12: Cotellic drug profile
  • Table 13: Cotellic Phase III trial in colorectal cancer
  • Table 14: Cotellic early-phase data in colorectal cancer
  • Table 15: Cotellic sales for colorectal cancer across the US and five major EU markets, by country ($m), 2016-25
  • Table 16: Patients treated with Cotellic in the US and five major EU markets, by country, 2016-25
  • Table 17: Cyramza drug profile
  • Table 18: Cyramza Phase III data in colorectal cancer
  • Table 19: Cyramza Phase I trials in colorectal cancer
  • Table 20: Cyramza sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 21: Patients treated with Cyramza across the US, Japan, and five major EU markets, by country, 2016-25
  • Table 22: Erbitux drug profile
  • Table 23: Overview of major approvals for Erbitux in colorectal cancer
  • Table 24: Erbitux Phase III data in colorectal cancer
  • Table 25: Erbitux Phase III data in colorectal cancer
  • Table 26: Erbitux sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 27: Patients treated with Erbitux across the US, Japan, and five major EU markets, by country, 2016-25
  • Table 28: Keytruda drug profile
  • Table 29: Keytruda Phase III trial in colorectal cancer
  • Table 30: Keytruda early-phase data in colorectal cancer
  • Table 31: Keytruda sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 32: Patients treated with Keytruda across the US, Japan, and five major EU markets, by country, 2016-25
  • Table 33: Lonsurf drug profile
  • Table 34: Lonsurf Phase III data in colorectal cancer
  • Table 35: Lonsurf Phase II trials in colorectal cancer
  • Table 36: Lonsurf sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 37: Patients treated with Lonsurf across the US, Japan, and five major EU markets, by country, 2016-25
  • Table 38: OncoVAX drug profile
  • Table 39: OncoVAX Phase III trial in colon cancer
  • Table 40: OncoVAX Phase III data in colon cancer
  • Table 41: OncoVAX sales for colon cancer in the US ($m), 2016-25
  • Table 42: Patients treated with OncoVAX in the US, 2016-25
  • Table 43: Opdivo drug profile
  • Table 44: Opdivo pivotal trial data in colorectal cancer
  • Table 45: Opdivo early-phase trials in colorectal cancer
  • Table 46: Opdivo sales for colorectal cancer across the US and five major EU markets, by country ($m), 2016-25
  • Table 47: Patients treated with Opdivo across the US and five major EU markets, by country, 2016-25
  • Table 48: Stivarga drug profile
  • Table 49: Stivarga pivotal trial data in colorectal cancer
  • Table 50: Stivarga ongoing trials in colorectal cancer
  • Table 51: Stivarga sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 52: Patients treated with Stivarga across the US, Japan, and five major EU markets, by country, 2016-25
  • Table 53: TS-1 drug profile
  • Table 54: TS-1 pivotal trial data in colorectal cancer
  • Table 55: TS-1 sales for colorectal cancer in Japan ($m), 2016-25
  • Table 56: Patients treated with TS-1 in Japan, 2016-25
  • Table 57: Tecentriq drug profile
  • Table 58: Tecentriq Phase III trial in colorectal cancer
  • Table 59: Tecentriq early-phase data in colorectal cancer
  • Table 60: Tecentriq sales for colorectal cancer across the US and five major EU markets, by country ($m), 2016-25
  • Table 61: Patients treated with Tecentriq in the US and five major EU markets, by country, 2016-25
  • Table 62: Vectibix drug profile
  • Table 63: Overview of major approvals for Vectibix in colorectal cancer
  • Table 64: Vectibix pivotal trial data in colorectal cancer
  • Table 65: Vectibix early-phase data in colorectal cancer
  • Table 66: Vectibix sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 67: Patients treated with Vectibix in the US, Japan, and five major EU markets, by country, 2016-25
  • Table 68: Zaltrap drug profile
  • Table 69: Zaltrap pivotal trial data in colorectal cancer
  • Table 70: Zaltrap sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 71: Patients treated with Zaltrap in the US, Japan, and five major EU markets, by country, 2016-25
  • Table 72: Binimetinib drug profile
  • Table 73: Binimetinib Phase III data in colorectal cancer
  • Table 74: Binimetinib sales for colorectal cancer across the US and five major EU markets, by country ($m), 2016-25
  • Table 75: Patients treated with binimetinib in the US and five major EU markets, by country, 2016-25
  • Table 76: Lefitolimod drug profile
  • Table 77: Lefitolimod Phase III trial in colorectal cancer
  • Table 78: Lefitolimod Phase II data in colorectal cancer
  • Table 79: Lefitolimod sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 80: Patients treated with lefitolimod across the US, Japan, and five major EU markets, by country, 2016-25
  • Table 81: Masitinib drug profile
  • Table 82: Masitinib Phase III trial in colorectal cancer
  • Table 83: Masitinib early-phase data in colorectal cancer
  • Table 84: Masitinib sales for colorectal cancer across the US and five major EU markets, by country ($m), 2016-25
  • Table 85: Patients treated with masitinib across the US and five major EU markets, by country, 2016-25
  • Table 86: Napabucasin drug profile
  • Table 87: Napabucasin Phase III trial in colorectal cancer
  • Table 88: Napabucasin Phase III data in colorectal cancer
  • Table 89: Napabucasin sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 90: Patients treated with napabucasin across the US, Japan, and five major EU markets, by country, 2016-25
  • Table 91: Medical oncologists and gastroenterologists surveyed for the colorectal cancer primary research study, 2016
  • Table 92: Colorectal cancer five-year survival rates, by stage at diagnosis
  • Table 93: TNM classification, by stage at diagnosis
  • Table 94: Leading treatments for colorectal cancer
  • Table 95: ICD-10 codes for primary sites of colorectal cancer cases
  • Table 96: Cancer registry databases used as a source of colorectal cancer incidence data, by country
  • Table 97: Forecasting methodology for colorectal cancer incidence, by country, cancer site, gender, and age group
  • Table 98: Data sources used for stage distribution of colorectal cancer, by country
  • Table 99: Sources of survival data used to estimate colorectal cancer prevalence, by country
  • Table 100: Validation of forecast estimates against benchmark estimates
  • Table 101: Incident cases of colorectal cancer in the US, Japan, and five major EU markets, by country, 2017-37
  • Table 102: AJCC TNM staging classification
  • Table 103: Profiled key marketed drugs for colorectal cancer
  • Table 104: Avastin drug profile
  • Table 105: Overview of major approvals for Avastin in colorectal cancer
  • Table 106: Avastin Phase III data in colorectal cancer
  • Table 107: Avastin sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 108: Patients treated with Avastin across the US, Japan, and five major EU markets, by country, 2016-25
  • Table 109: Cyramza drug profile
  • Table 110: Cyramza Phase III data in colorectal cancer
  • Table 111: Cyramza Phase I trials in colorectal cancer
  • Table 112: Cyramza sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 113: Patients treated with Cyramza across the US, Japan, and five major EU markets, by country, 2016-25
  • Table 114: Erbitux drug profile
  • Table 115: Overview of major approvals for Erbitux in colorectal cancer
  • Table 116: Erbitux Phase III data in colorectal cancer
  • Table 117: Erbitux Phase III data in colorectal cancer
  • Table 118: Erbitux sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 119: Patients treated with Erbitux across the US, Japan, and five major EU markets, by country, 2016-25
  • Table 120: Keytruda drug profile
  • Table 121: Keytruda Phase III trial in colorectal cancer
  • Table 122: Keytruda early-phase data in colorectal cancer
  • Table 123: Keytruda sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 124: Patients treated with Keytruda across the US, Japan, and five major EU markets, by country, 2016-25
  • Table 125: Lonsurf drug profile
  • Table 126: Lonsurf Phase III data in colorectal cancer
  • Table 127: Lonsurf Phase II trials in colorectal cancer
  • Table 128: Lonsurf sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 129: Patients treated with Lonsurf across the US, Japan, and five major EU markets, by country, 2016-25
  • Table 130: Opdivo drug profile
  • Table 131: Opdivo pivotal trial data in colorectal cancer
  • Table 132: Opdivo early-phase trials in colorectal cancer
  • Table 133: Opdivo sales for colorectal cancer across the US and five major EU markets, by country ($m), 2016-25
  • Table 134: Patients treated with Opdivo across the US and five major EU markets, by country, 2016-25
  • Table 135: Stivarga drug profile
  • Table 136: Stivarga pivotal trial data in colorectal cancer
  • Table 137: Stivarga ongoing trials in colorectal cancer
  • Table 138: Stivarga sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 139: Patients treated with Stivarga across the US, Japan, and five major EU markets, by country, 2016-25
  • Table 140: TS-1 drug profile
  • Table 141: TS-1 pivotal trial data in colorectal cancer
  • Table 142: TS-1 sales for colorectal cancer in Japan ($m), 2016-25
  • Table 143: Patients treated with TS-1 in Japan, 2016-25
  • Table 144: Vectibix drug profile
  • Table 145: Overview of major approvals for Vectibix in colorectal cancer
  • Table 146: Vectibix pivotal trial data in colorectal cancer
  • Table 147: Vectibix early-phase data in colorectal cancer
  • Table 148: Vectibix sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 149: Patients treated with Vectibix in the US, Japan, and five major EU markets, by country, 2016-25
  • Table 150: Zaltrap drug profile
  • Table 151: Zaltrap pivotal trial data in colorectal cancer
  • Table 152: Zaltrap sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 153: Patients treated with Zaltrap in the US, Japan, and five major EU markets, by country, 2016-25
  • Table 154: Profiled pipeline products in development for colorectal cancer
  • Table 155: Cotellic drug profile
  • Table 156: Cotellic Phase III trial in colorectal cancer
  • Table 157: Cotellic early-phase data in colorectal cancer
  • Table 158: Cotellic sales for colorectal cancer across the US and five major EU markets, by country ($m), 2016-25
  • Table 159: Patients treated with Cotellic in the US and five major EU markets, by country, 2016-25
  • Table 160: OncoVAX drug profile
  • Table 161: OncoVAX Phase III trial in colon cancer
  • Table 162: OncoVAX Phase III data in colon cancer
  • Table 163: OncoVAX sales for colon cancer in the US ($m), 2016-25
  • Table 164: Patients treated with OncoVAX in the US, 2016-25
  • Table 165: Tecentriq drug profile
  • Table 166: Tecentriq Phase III trial in colorectal cancer
  • Table 167: Tecentriq early-phase data in colorectal cancer
  • Table 168: Tecentriq sales for colorectal cancer across the US and five major EU markets, by country ($m), 2016-25
  • Table 169: Patients treated with Tecentriq in the US and five major EU markets, by country, 2016-25
  • Table 170: Binimetinib drug profile
  • Table 171: Binimetinib Phase III data in colorectal cancer
  • Table 172: Binimetinib sales for colorectal cancer across the US and five major EU markets, by country ($m), 2016-25
  • Table 173: Patients treated with binimetinib in the US and five major EU markets, by country, 2016-25
  • Table 174: Encorafenib drug profile
  • Table 175: Encorafenib Phase III data in colorectal cancer
  • Table 176: Encorafenib Phase II data in colorectal cancer
  • Table 177: Encorafenib sales for colorectal cancer across the US and five major EU markets, by country ($m), 2016-25
  • Table 178: Patients treated with encorafenib across the US and five major EU markets, by country, 2016-25
  • Table 179: Lefitolimod drug profile
  • Table 180: Lefitolimod Phase III trial in colorectal cancer
  • Table 181: Lefitolimod Phase II data in colorectal cancer
  • Table 182: Lefitolimod sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 183: Patients treated with lefitolimod across the US, Japan, and five major EU markets, by country, 2016-25
  • Table 184: Masitinib drug pro
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.